Cambridge Nucleomics

Cambridge Nucleomics is pioneering a novel diagnostic platform using soluble nanoarrays and nanopore detection to quantify nucleic acids with unprecedented speed and multiplexing. Its lead program focuses on a one-hour point-of-care test for sepsis pathogen ID and antimicrobial resistance profiling, aiming to guide therapy within the critical 'golden hour'. The company, led by a team with strong scientific and commercial diagnostics expertise, is positioned to address major bottlenecks in molecular diagnostics by simplifying workflows and enabling rapid, decentralized testing.

Proprietary enzyme-free Modular Soluble Nanoarray platform. It uses nanotechnology barcodes hybridized to target nucleic acids, with detection via nanopore sensors that translate barcode structure into characteristic electrical signals for single-molecule counting.

The company competes in the molecular diagnostics space against established PCR-based rapid diagnostics (e.g., BioFire FilmArray) and emerging next-generation sequencing platforms. Its key differentiators are the claimed one-hour turnaround for high-plex (200-plex) detection and an enzyme-free, simplified workflow, but it must prove these advantages in clinical practice.